CAPTRUST Financial Advisors
AKRO

CAPTRUST Financial Advisors’s Akero Therapeutics AKRO Stock Holding History

CAPTRUST Financial Advisors’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-53
Closed -$1K – 2116
2022
Q2 		$1K Buy
+53
New +$553 ﹤0.01% 4618
2022
Q1 		– Sell
-88
Closed -$2K – 4902
2021
Q4 		$2K Sell
88
-53
-38% -$1.18K ﹤0.01% 4384
2021
Q3 		$3K Buy
+141
New +$3.19K ﹤0.01% 4104

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
YCM
Yiheng Capital Management San Francisco, California $231M AUM 29.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

CAPTRUST Financial Advisors's AKRO Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Akero Therapeutics (AKRO) in Q3 2022, closing a stake of 53 shares — an estimated $1K sold.

CAPTRUST Financial Advisors first reported a position in AKRO in Q3 2021 and held it in 3 quarters. The position peaked at $3K in Q3 2021. 146 funds tracked by Wall St. Rank hold AKRO as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Akero Therapeutics position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 53 Akero Therapeutics shares in Q3 2022, an estimated $1K.
  • CAPTRUST Financial Advisors first reported a position in Akero Therapeutics in Q3 2021 and held it in 3 quarters.
  • CAPTRUST Financial Advisors's Akero Therapeutics position peaked at $3K in Q3 2021.
  • 146 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.